The Protek Group introduced a new antiepileptic medication, Novolera EPI (lacosamide), produced by Rafarma JSC, at major scientific events across the country.
At the expert council of the Russian Antiepileptic League, led by Professor Sergey Burda, specialists discussed the current potential of the drug in treating epilepsy in adults of various ages, with different etiologies and associated comorbidities. The participants of the event highlighted the proven efficacy and high tolerability of lacosamide, as well as its minimal risk of drug interactions and suitability for use in patients with comorbid conditions. Following the meeting, epileptologists received guidelines on the clinical application of Novolera EPI.
At the XIV International Forum of Epileptologists of the CIS countries and the EAEU Epineuro Forum 2025, held at the Federal Center for Brain and Neurotechnology of the FMBA of Russia, experts emphasized the drug’s effectiveness both as monotherapy and in combination with other medications for the treatment of focal epilepsy. They also highlighted its favorable pharmacokinetic profile.
The drug was also presented at the III International Congress Comorbid Neurology 2025, where strategies for treating patients with combined neurological and mental health conditions were discussed. Experts noted the efficacy and safety of lacosamide in complex clinical cases and the relevance of its use for practitioners. Meanwhile, the drug was also discussed as an effective remedy for the treatment of focal forms of epilepsy in children from the age of four at the II Scientific and Practical Conference “Neurogenetic diseases, Cerebral Palsy, and Epilepsy”.